IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Clearstead Trust LLC

Clearstead Trust LLC increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 25.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 360 shares of the medical research company’s stock after acquiring an additional 72 shares during the period. Clearstead Trust LLC’s holdings in IQVIA were worth $76,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Virtu Financial LLC grew its holdings in IQVIA by 302.1% during the second quarter. Virtu Financial LLC now owns 15,574 shares of the medical research company’s stock worth $3,293,000 after acquiring an additional 11,701 shares during the period. Edgestream Partners L.P. acquired a new position in IQVIA during the second quarter worth $5,038,000. Primecap Management Co. CA grew its holdings in IQVIA by 0.4% in the second quarter. Primecap Management Co. CA now owns 325,176 shares of the medical research company’s stock valued at $68,755,000 after purchasing an additional 1,220 shares during the last quarter. GDS Wealth Management grew its holdings in IQVIA by 10.8% in the second quarter. GDS Wealth Management now owns 50,837 shares of the medical research company’s stock valued at $10,749,000 after purchasing an additional 4,968 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in IQVIA in the second quarter valued at $70,610,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several research reports. Truist Financial upped their target price on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Robert W. Baird upped their target price on IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group initiated coverage on IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price on the stock. Morgan Stanley upped their target price on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Finally, Royal Bank of Canada started coverage on IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $266.67.

IQVIA Stock Performance

NYSE IQV opened at $239.38 on Tuesday. The business’s 50-day moving average price is $238.59 and its 200 day moving average price is $234.21. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a market capitalization of $43.64 billion, a PE ratio of 32.70, a price-to-earnings-growth ratio of 2.24 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the prior year, the business posted $2.22 earnings per share. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, research analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is currently owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.